Date and Time: *Wednesday 6th February 2013, 10:00 – 16:30*

Minutes:

Lipid Modification Guideline

Guideline Development Group Meeting 4

Place: Sloane room, Royal College of Physicians
11 St Andrews Place, Regent's Park, London NW1 4LE

GDG Present:	Anthony Wierzbicki (Chair)	(Present for notes 1 – 8)
	Rajai Ahmad	(Present for notes 1 – 8)
	Lindsay Banks	(Present for notes 1 – 8)
	Gary Collins (cooptee)	(Present for note 6)
	Eleanor Grey	(Present for notes 1 –8)
	Michael Khan	(Present for notes 1 – 8)
	Emma McGowan	(Present for notes 1 – 8)
	Dermot Neely	(Present for notes 1 – 8)
	Nadeem Qureshi	(Present for notes 1 – 8)
	Alan Rees	(Present for notes 1 – 8)
	David Wald	(Present for notes 1– 8)
NCGC Present:	Martin Harker	(Present for notes 1 – 8)
	Norma O'Flynn	(Present for notes 1 – 8)
	Silvia Rabar	(Present for notes 1 – 8)
	Lina Gulhane	(Present for notes 1 – 8)

In attendance:

NICE Staff:		

Observers:

Mark Perry	Research Fellow, NCGC	Present for note 6
Serena Carville	Senior Research Fellow and Project manager, NCGC	Present for note 6
Emmert Roberts	Research Fellow, NCGC	Present for note 6

Agenda item

1. **Welcome introductions and apologies**
Anthony Wierzbicki welcomed the group to the third meeting of this GDG and thanked them for their time and commitment to the guideline. Apologies were received from Alison Richards, Liz Clark, Martin Duerden, Angela Cooper and Clifford Middleton.

2. **Declaration of Interests**
The Chair asked all GDG members to declare any new relevant conflicts of interest. The group then verbally declared the following new DOIs:

Michael Khan:
- Personal pecuniary interest: Part time salaried position as Chief Medical Officer of Silence Therapeutics. This is an RNAi therapy development company.
- Non-personal pecuniary interest: Clinical trial of a new monoclonal antibody directed at

PCSK9 to be run at UHCW later this year.
- Personal non-pecuniary interest: Chair and Director of the Warwick University Masters Program in Cardiovascular Risk.

Dermot Neely:
- Personal pecuniary interest: In 2011-2012 I participated in one-off Advisory Boards for pharmaceutical companies developing lipid modifying therapy for specialist use in poorly treatment responsive and/or severe inherited lipid disorders, including Roche Pharma (dalcetrapib), Genzyme (mipomersen), and Aegerion (lomitapide). I have been invited by Sanofi UK & Ireland to participate in the UK Lipid Strategic Advisory Board to be held on Friday 12th April 2013, regarding a new product in development for treatment of hypercholesterolaemia, for which I will receive an honorarium.
- Non-personal pecuniary interest: Newcastle upon Tyne Hospitals NHS Foundation Trust /Newcastle University Clinical Research Facility participates in commercial clinical trials including those of novel lipid lowering therapy for Familial Hypercholesterolaemia, for which I have had responsibility for recruiting some of the eligible patients.
- Personal non-pecuniary interest: I am a Trustee and Board member of HEART UK the Cholesterol Charity and Co-Chairman of the Familial Hypercholesterolaemia Guideline Implementation Group, a multi-disciplinary team which since 2008 has campaigned for the full implementation in England of the NICE Clinical Guideline CG71 and has developed and published a Guideline Implementation Toolkit on the HEART UK Web site.

Alan Rees:
- Personal pecuniary interest: I gave 2 lectures on 9th October 2012 (Midland Hotel, Manchester) and 10th October 2012 (London, Connaught Rooms) for Primed Educational Programmes. The Meeting was entitled Cardiac Commissioning Meeting and I gave a talk on New Drugs in the Pipeline for the Treatment of Dyslipidaemias. I received a speaker fee and travelling expenses. The Meeting was sponsored by MSD and organised by Primed Educational Programmes Ltd. On November 21st 2012 I attended the ABPI Wales Dinner in Cardiff as a guest of Abbott Healthcare.I gave a lecture on the forthcoming JBS3 Guidelines to the North West Lipid Forum on Tuesday December 4th 2012. I will receive travelling expenses and a speaker fee. The Meeting was sponsored by an educational grant from MSD.On April 12th 2013 I have been invited (and accepted) to attend a Sanofi Pharmaceutical Advisory Board. This is to advise on the development of a new monoclonal PCSK9 antibody for the treatment of severe hypercholesterolaemia. This product is not licensed but is under development.On Wednesday 27th February 2013 I have agreed to give a talk on Developing Diabetic Services in the Locality. I will receive a speaker fee. This lecture will not refer to any pharmaceutical product but is on the context of a day long symposium sponsored by Bristol Myers Squibb and AstraZeneca.

Nadeem Qureshi:
- Non-personal pecuniary interest: I am supervising a PhD looking at new metrics to assess risk prediction models. As part of this organising a CME sessions for General Practitioners on risk prediction models

Statins review strategy.
The GDG discussed the approach presented at the previous GDG meeting and implications of the different options.

3. **Review question: For adults with and without CVD, what is the clinical and cost effectiveness of omega 3 fatty acids versus placebo in preventing cardio-vascular disease?**
The Chair introduced Silvia Rabar (Senior Project Manager and Research Fellow at NCGC) and Martin Harker (Health Economist at NCGC) who gave a presentation on the clinical and cost effectiveness of omega 3 fatty acids for the prevention of cardio-vascular disease, and took questions from the group. The GDG then discussed the clinical

Agenda item

questions in relation to this guideline and developed draft recommendations. The Chair thanked Silvia Rabar and Martin Harker for their presentation.

4. **Review question: What is the clinical and cost effectiveness of interventions that improve adherence to statin therapy for adults without established CVD (primary prevention) and with established CVD (secondary prevention)?**
The Chair introduced Silvia Rabar (Senior Project Manager and Research Fellow at NCGC) and Martin Harker (Health Economist at NCGC) who gave a presentation on the interventions to improve adherence to statin therapy, and took questions from the group. The GDG then discussed the clinical questions in relation to this guideline and developed draft recommendations. The Chair thanked Silvia Rabar and Martin Harker for their presentation.

5. **Overview of second-line treatments: bile acid sequestrants (anion exchange resins), nicotinic acids, fibrates, omega-3 fatty acids**
The Chair gave a summary presentation on the second line treatments and recommendations. The GDG agreed with the recommendations drafted so far.

6. **Introduction to risk assessment tools**
The Chair introduced Gary Collins (Senior Medical Statistician, University of Oxford) who gave a presentation on risk assessment tools and took questions from the group. The GDG discussed the different options and agreed the protocols.

7. **Health economics plan**
The economic plan was discussed and the GDG agreed the prioritisations within.

8. **Summary of next steps and any other business**
There were no other businesses to discuss. The Chair closed the meeting and thanked everybody for attending.

Date, time and venue of the next meeting

Friday 15th March 2013, 10.00 – 13.00, via Web-ex and teleconference.